BRCA2 and posterior cortical atrophy: Accumulating evidence has shown that BRCA2 pathogenic variants (PVs) carriers are at higher risk of developing prostate cancer (PCa), estimated to be 2.5–8.6 fold, and that their disease progression is especially accelerated.1, 2, 3, 4